This document summarizes key findings from studies on intensive hemodialysis and its impact on mineral and bone disorder and phosphate binder use. It reports that intensive hemodialysis through daily or nocturnal treatment reduced serum phosphorus levels compared to conventional hemodialysis, where levels increased over time. Intensive hemodialysis also significantly reduced the need for and dosage of phosphate binders. In one study, the percentage of patients using any phosphate binders decreased from 97% at baseline to 27% after 10-12 months of intensive nocturnal hemodialysis.
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
Bill Faloon Age Reversal Update at DaVinci 50 Masters Conference 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects for human age reversal medicine at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
Update on the 18th International Conference on Co-morbidities and Adverse Drug Reactions in HIV
Daniel Lee, M.D.
January 20th, 2017
UCSD HIV & Global Health Rounds
Hypokalemic and Thyrotoxic Periodic Paralysismfabzak
Poster presentation prepared with medical students, Sarah Goaslind, and Matthew Koller.
Presentation of an individual with acute onset weakness of upper and lower extremities. Found to have significant hypokalemia and hyperthyroidism. The discussion emphasized the importance of assessment of thyroid function in individuals presenting with hypokalemic paralysis as well as possible mutations in potassium channels that increase susceptibility to thyrotoxic periodic paralysis.
Cathy Logan, MD, of the UC San Diego AntiViral Research Center, presents "Solid Organ Transplantation and HIV" at AIDS Clinical Rounds on August 29, 2014
Bill Faloon at DaVinci 50 about stroke risk and blood pressuremaximuspeto
In this presentation on Thursday April 29th, 2021 at the DaVinci 50 Mastermind Conference in Key Largo, Florida, Bill Faloon discusses how to optimize blood pressure to reduce stroke risk.
Bill Faloon Age Reversal Update at DaVinci 50 Masters Conference 2021maximuspeto
In this presentation, Bill Faloon gives an update on the prospects for human age reversal medicine at the DaVinci 50 Masters Conference in Key Largo, Florida on April 29th, 2021.
Update on the 18th International Conference on Co-morbidities and Adverse Drug Reactions in HIV
Daniel Lee, M.D.
January 20th, 2017
UCSD HIV & Global Health Rounds
Hypokalemic and Thyrotoxic Periodic Paralysismfabzak
Poster presentation prepared with medical students, Sarah Goaslind, and Matthew Koller.
Presentation of an individual with acute onset weakness of upper and lower extremities. Found to have significant hypokalemia and hyperthyroidism. The discussion emphasized the importance of assessment of thyroid function in individuals presenting with hypokalemic paralysis as well as possible mutations in potassium channels that increase susceptibility to thyrotoxic periodic paralysis.
Cathy Logan, MD, of the UC San Diego AntiViral Research Center, presents "Solid Organ Transplantation and HIV" at AIDS Clinical Rounds on August 29, 2014
Studies showed that RBO has important hypocholesterolemic effects. RBO
incorporates a healthy diet and fitness regimen to improve cardiac health
and other health conditions. It is important to remind everyone that RBO is
not a drug, even with minor changes in your lipid profile. This concept
could be beneficial. It is a convenient and cost-effective approach to a well-balanced life and better quality of life.
Do we-have-the-right-dose-dose-adjustments-for-organ-dysfunction-2167-7700.10...science journals
The effect of heat treatment on the activities of three quality related enzymes peroxidase (POD), polyphenol oxidase (PPO), and lipoxygenase (LOX), from edible white yam (Dioscorea rotundata) was studied over a temperature range of 50 to 80°C using mathematical analysis of the kinetic and thermodynamic parameters for the thermoinactivation of the enzymes.
Background: Chronic kidney disease affects one in five adults ≥65 years old, over half of whom develop secondary hyperparathyroidism. In observational studies, secondary hyperparathyroidism is associated with low bone mineral density and excess vascular calcification, presumably leading to surplus fractures, more cardiovascular events and shortened lifespan. Several bioactive vitamin D analogs are FDA approved to treat secondary hyperparathyroidism and published algorithms direct their clinical use. However, whether such therapy improves patient outcomes is uncertain. The purpose of this review is to summarize evidence derived from clinical trials describing the benefits of treating secondary hyperparathyroidism in patients with Pre-dialysis chronic kidney disease.
Methods: We performed a systematic review of the literature to identify trials using bioactive vitamin D (calcitriol, alfacalcidol, paricalcitol and doxercalciferol) to treat secondary hyperparathyroidism in chronic kidney disease patients. We focused on changes in bone mineral density, fractures, falls, vascular events and lifespan, resulting from treatment of secondary hyperparathyroidism.
Background: High serum phosphate level is associated with increased CVD morbidity and mortality in CKD patients. We sought to compare the efϐicacy of non-calcium containing phosphate binder Sevelamer Carbonate (SC) with Lanthanum Carbonate (LC) in patients with CKD stage 3-5.
This presentation reviews ETC participant assessment, aggregation, and payment mechanisms, including achievement benchmarks for measurement years 1-, 2-, and 3-.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
1. Intensive Hemodialysis, Mineral and Bone
Disorder and Phosphate Binder Use
Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA. Intensive
Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. American
Journal of Kidney Diseases, Volume 68, Issue 5, S24 - S32.
2. Serum phosphorus levels
have remained relatively
unchanged from 2010 to
2015.2
SOURCE: US-DOPPS PRACTICE MONITOR
Most recent single monthly value.
Facility sample transitioned from DOPPS 4
to 5 in Jan-Apr 2012. Facility sample
transitioned from DOPPS 5 to 6 in Mar-Jul
2015.
1Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for
dialysis patients with different levels of serum calcium,
phosphorus, and PTH: the Dialysis Outcomes and Practice
Patterns Study (DOPPS). Am J Kidney Dis Off J Natl Kidney
Found. 2008;52(3):519-530. doi:10.1053/j.ajkd.2008.03.020.
2The DOPPS Practice Monitor. http://www.dopps.org/DPM/.
Accessed November 8, 2016.
Serum phosphorus levels of 5.0 and 5.5
mg/dL have been associated with increased
cardiovascular risk.1
3. In 2015, over 36% of hemodialysis patients
had serum phosphorus persistently above
the target range.1
1The DOPPS Practice Monitor. http://www.dopps.org/DPM/. Accessed May 20,
2015.
An additional 15% to 20% of patients
had serum phosphorus levels between
5.0 and 5.5 mg/dL.1
CHAPTER 3, FIGURE 1:
Distribution of 3-month mean serum phosphorus in the
Dialysis Outcomes and Practice Patterns Study Practice
Monitor, December 2015.1
4. 1Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 Annual Data
Report. Am J Kidney Dis Off J Natl Kidney Found. 2014;63(1 Suppl):A7.
doi:10.1053/j.ajkd.2013.11.001. 2Saran R, Li Y, Robinson B, et al. US Renal Data
System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United
States. Am J Kidney Dis Off J Natl Kidney Found. 2016;67(3 Suppl 1):A7-A8.
doi:10.1053/j.ajkd.2015.12.014.
Under perfect adherence, the cost of phosphate
binders to all payers would be enormous.1
Medicare Part D expenditures for phosphate binders
and calcimimetics exceed $1 billion annually.2
Expenditures for phosphate binders
were noticeably higher in a large
dialysis provider organization that
delivers integrated pharmacy services
to support medication adherence.1
CHAPTER 3, FIGURE 2:
Medicare Part D gross costs per patient-year for phosphate
binders, by dialysis provider organization or class, 2011.
Abbreviations: FDF, free-standing dialysis facility; HDF,
hospital-based dialysis facility; SDO, small dialysis
organization.
5. 1Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on
measures of CKD mineral and bone disorder. J Am Soc Nephrol JASN.
2012;23(4):727-738. doi:10.1681/ASN.2011070688. 2Culleton BF, Walsh M,
Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional
hemodialysis on left ventricular mass and quality of life: a randomized controlled
trial. JAMA. 2007;298(11):1291-1299. doi:10.1001/jama.298.11.1291.
The FHN Daily, Nocturnal and a Canadian
trial of nocturnal hemodialysis reported
reductions in mean serum phosphorus
from baseline to follow-up.1,2
In the conventional hemodialysis
group, serum phosphorus increased
over time.1,2
CHAPTER 3, FIGURE 3:
Effects of intensive versus conventional hemodialysis on
serum phosphorus in the FHN Daily Trial,1 the FHN
Nocturnal Trial,1 and the Canadian trial of nocturnal
hemodialysis.2
Estimated treatment effects (solid dots) and associated
95% confidence intervals (solid lines) are displayed at the
bottom.
-0.46 mg/dL
-1.5 mg/dL
-1.11 mg/dL
6. 1Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on
measures of CKD mineral and bone disorder. J Am Soc Nephrol JASN.
2012;23(4):727-738. doi:10.1681/ASN.2011070688.
In the FHN Daily Trial, mean estimated pill
burden per day declined from 7.17 pills per
day at baseline to 5.70 after 10 to 12
months.1
CHAPTER 3, FIGURE 4:
Mean equivalent phosphorus binding dose for intensive
versus conventional hemodialysis in the FHN Daily Trial.
Dashed bars span one standard deviation above and below
the mean.
20%
DECREASE
10-12 MONTHS
7. 1Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on
measures of CKD mineral and bone disorder. J Am Soc Nephrol JASN.
2012;23(4):727-738. doi:10.1681/ASN.2011070688.
In the FHN Nocturnal Trial, the percentage of
patients using any phosphate binders
decreased with intensive hemodialysis, from
97% at baseline to 27% after 10 to 12
months.1
CHAPTER 3, FIGURE 5:
Distribution of equivalent phosphorus binding
dose (EPBD) for intensive versus conventional
hemodialysis in the FHN
Nocturnal Trial.1